These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

863 related articles for article (PubMed ID: 33919317)

  • 21. Disease Modeling of Neurodegenerative Disorders Using Direct Neural Reprogramming.
    Legault EM; Bouquety J; Drouin-Ouellet J
    Cell Reprogram; 2022 Oct; 24(5):228-251. PubMed ID: 35749150
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human Pluripotent Stem Cells in Neurodegenerative Diseases: Potentials, Advances and Limitations.
    Kolagar TA; Farzaneh M; Nikkar N; Khoshnam SE
    Curr Stem Cell Res Ther; 2020; 15(2):102-110. PubMed ID: 31441732
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Induced pluripotent stem cell technology for modelling and therapy of cerebellar ataxia.
    Watson LM; Wong MM; Becker EB
    Open Biol; 2015 Jul; 5(7):150056. PubMed ID: 26136256
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potential therapeutic applications of differentiated induced pluripotent stem cells (iPSCs) in the treatment of neurodegenerative diseases.
    Gao A; Peng Y; Deng Y; Qing H
    Neuroscience; 2013 Jan; 228():47-59. PubMed ID: 23069758
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modeling neurodegenerative diseases with patient-derived induced pluripotent cells: Possibilities and challenges.
    Poon A; Zhang Y; Chandrasekaran A; Phanthong P; Schmid B; Nielsen TT; Freude KK
    N Biotechnol; 2017 Oct; 39(Pt B):190-198. PubMed ID: 28579476
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The application of in vitro-derived human neurons in neurodegenerative disease modeling.
    D'Souza GX; Rose SE; Knupp A; Nicholson DA; Keene CD; Young JE
    J Neurosci Res; 2021 Jan; 99(1):124-140. PubMed ID: 32170790
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Induced Neurons for the Study of Neurodegenerative and Neurodevelopmental Disorders.
    Sauter EJ; Kutsche LK; Klapper SD; Busskamp V
    Methods Mol Biol; 2019; 1942():101-121. PubMed ID: 30900179
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Human Glial Chimeric Mice to Define the Role of Glial Pathology in Human Disease.
    Mariani JN; Zou L; Goldman SA
    Methods Mol Biol; 2019; 1936():311-331. PubMed ID: 30820907
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neural differentiation of induced pluripotent stem cells.
    Denham M; Dottori M
    Methods Mol Biol; 2011; 793():99-110. PubMed ID: 21913096
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The application of iPSCs in Parkinson's disease.
    Jarbæk Nielsen JJ; Lillethorup TP; Glud AN; Hedemann Sørensen JC; Orlowski D
    Acta Neurobiol Exp (Wars); 2020; 80(3):273-285. PubMed ID: 32990285
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Induced pluripotent stem cell-derived neural cells survive and mature in the nonhuman primate brain.
    Emborg ME; Liu Y; Xi J; Zhang X; Yin Y; Lu J; Joers V; Swanson C; Holden JE; Zhang SC
    Cell Rep; 2013 Mar; 3(3):646-50. PubMed ID: 23499447
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CRISPR and iPSCs: Recent Developments and Future Perspectives in Neurodegenerative Disease Modelling, Research, and Therapeutics.
    Sen T; Thummer RP
    Neurotox Res; 2022 Oct; 40(5):1597-1623. PubMed ID: 36044181
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Induced Pluripotent Stem Cell (iPSC)-Based Neurodegenerative Disease Models for Phenotype Recapitulation and Drug Screening.
    Chang CY; Ting HC; Liu CA; Su HL; Chiou TW; Lin SZ; Harn HJ; Ho TJ
    Molecules; 2020 Apr; 25(8):. PubMed ID: 32344649
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mitochondrial dysfunction in neurodegenerative diseases: A focus on iPSC-derived neuronal models.
    Trombetta-Lima M; Sabogal-Guáqueta AM; Dolga AM
    Cell Calcium; 2021 Mar; 94():102362. PubMed ID: 33540322
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Establishment of stable iPS-derived human neural stem cell lines suitable for cell therapies.
    Rosati J; Ferrari D; Altieri F; Tardivo S; Ricciolini C; Fusilli C; Zalfa C; Profico DC; Pinos F; Bernardini L; Torres B; Manni I; Piaggio G; Binda E; Copetti M; Lamorte G; Mazza T; Carella M; Gelati M; Valente EM; Simeone A; Vescovi AL
    Cell Death Dis; 2018 Sep; 9(10):937. PubMed ID: 30224709
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel human iPSC models of neuroinflammation in neurodegenerative disease and regenerative medicine.
    Summers RA; Fagiani F; Rowitch DH; Absinta M; Reich DS
    Trends Immunol; 2024 Oct; 45(10):799-813. PubMed ID: 39307583
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Human induced pluripotent stem cells and neurodegenerative disease: prospects for novel therapies.
    Jung YW; Hysolli E; Kim KY; Tanaka Y; Park IH
    Curr Opin Neurol; 2012 Apr; 25(2):125-30. PubMed ID: 22357218
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Glia in Neurodegeneration: The Housekeeper, the Defender and the Perpetrator.
    Sheeler C; Rosa JG; Ferro A; McAdams B; Borgenheimer E; Cvetanovic M
    Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33276471
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Disease modeling using human induced pluripotent stem cell-derived microglia and region-specific neurons].
    Nishimura K; Takata K
    Nihon Yakurigaku Zasshi; 2023; 158(1):52-56. PubMed ID: 36596492
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 2D versus 3D human induced pluripotent stem cell-derived cultures for neurodegenerative disease modelling.
    Centeno EGZ; Cimarosti H; Bithell A
    Mol Neurodegener; 2018 May; 13(1):27. PubMed ID: 29788997
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 44.